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Introduction
Multiple sclerosis (MS) is a disease characterized by chronic inflammatory demyelination and axonal injury of white matter in the central nervous system (CNS) [1] . MS is caused by intricate interactions between genetic predisposition and environmental triggers, including viral infection [2] . Large-scale studies have confirmed that EpsteinBarr virus (EBV) is the only viral agent that is associated positively with MS with no signs of bias [3, 4] . The seropositivity rate of EBV in MS patients was 99Á5% and both anti-EBV capsid antigen (EBVCA) and anti-EB nuclear antigen (EBNA) titres were increased in MS patients [5] [6] [7] [8] [9] . EBV infection may be a prerequisite for the development of MS [10] [11] [12] [13] [14] [15] . However, the underlying molecular mechanisms of this association remain unclear.
Interestingly, recent studies have demonstrated that EBV encodes 44 evolutionarily conserved microRNAs (miRNAs) which are classified into two clusters, the BamHI fragment H rightward open reading frame 1 (BHRF1) and BamHI A rightward transcripts (BART) clusters [16, 17] . EBV miRNAs may serve as biomarkers for EBV-related diseases, including nasopharyngeal carcinoma, leukaemia and chronic active EBV infection [18] [19] [20] [21] . Additionally, EBV miRNAs are a novel class of pathogenic molecules of EBV that can specifically reflect the EBV proliferation and influence the immune response by regulating viral and host cellular genes [22] [23] [24] [25] [26] . However, the expression of EBV miRNAs in MS patients and its connection with the pathogenesis of MS have not been investigated systematically. To fill this gap, we performed a study measuring the expression levels of EBV miRNAs in MS and preliminarily validated the potential target genes of the significantly altered EBV miRNAs.
Materials and methods

Study subjects
Conforming to the ethical guidelines of the Declaration of Helsinki, the study protocol was approved by the Institutional Review Board of Harbin Medical University, Harbin, China. A signed informed consent was obtained from each participant before collecting blood samples. Clinically diagnosed relapsing-remitting MS (RRMS) patients at relapse (n 5 30) and age/gender-matched healthy controls (n 5 30) were recruited from the Neurology Department of the 2nd Affiliated Hospital of Harbin Medical University between 1 September 2014 and 15 June 2016. The mean time between the onset of symptoms of a relapse and the time of blood collection is 5Á5 days. The baseline characteristics of the study subjects are listed in Table 1. . Regarding inclusion criteria, (1) clinical diagnoses were confirmed using the 2010 revisions to the McDonald diagnostic criteria for multiple sclerosis; and (2) all participants were on periods of relapse and EBV-immunoglobulin (Ig)G-positive but EBV-IgM-negative. Regarding exclusion criteria, (1) primary progressive and paediatric MS cases were excluded; (2) patients who met the diagnostic criteria of other systemic autoimmune diseases involving central nervous system (CNS) demyelination were excluded; and (3) patients who received treatment within the previous 60 days were also excluded.
Serum collection and RNA isolation
Venous blood (10 ml) was drawn into a sterile tube with no anti-coagulant prior to therapy. The tubes were placed upright for 20 min, and samples were centrifuged at 1500 g for 10 min at 208C. Supernatant sera were harvested immediately and stored at 2808C for analysis.
For quantitative real-time polymerase chain reaction (qRT-PCR) assay, a well-vortexed mixture of 100 ll of serum, 200 ll of acid phenol, 200 ll of chloroform and 300 ll of RNase-free water was made. Then the mixture was centrifuged at 16 000 g at 208C for 15 min for phase separation. The aqueous layer was harvested and mixed with 1Á5 volumes of isopropyl alcohol and 0Á1 volume of sodium acetate (3 mol/l, pH 5 5Á3). The solution was conserved at 2208C for 2 h. The RNA pellet was collected by centrifugation at 16 000 g for 15 min at 48C. The resulting pellet was washed twice with 750 ml/l ethanol and dried for 20 min at 208C. The pellet was dissolved in 20 ll of RNase-free water and conserved at 2808C for analysis.
Individual quantitative reverse-transcription polymerase chain reaction assay
According to the manufacturer's instructions (7500 Sequence Detection System; Applied Biosystems, Foster City, CA, USA) with a minor modification, TaqMan probebased qRT-PCR assays were performed to determine the miRNAs threshold cycle (Ct) value of each serum sample. Briefly, the reverse transcription reaction was performed in 10 ll solution containing RNA (2 ll), 10 mmol/l deoxynucleotides (dNTPs) (1 ll; TaKaRa, Shiga, Japan), avian myeloblastosis virus (AMV) reverse transcriptase (0Á5 ll; TaKaRa), a stem-loop RT primer (1 ll; Applied Biosystems), 53 reverse transcription buffer (2 ll) and diethylpyrocarbonate (DEPC) water (3Á5 ll). For cDNA synthesis, the mixtures were incubated at 168C for 30 min, 428C for 30 min, 858C for 5 min and then held at 48C. Real-time PCR was performed using an Applied Biosystems 7500 Sequence Detection System as follows: 5 min initial hold at 958C, followed by 40 cycles of 958C for 15 s and 608C for 1 min. Reactions were performed in a final volume of 20 ll containing cDNA (1 ll), TaqMan hydrolysis probe (0Á33 ll; Applied Biosystems), rTaq (0Á3 ll; TaKaRa), 10 mmol/l dNTPs (0Á4 ll; TaKaRa), 25 mmol/l MgCl 2 (1.2 ll), 103 PCR buffer (2 ll) and DEPC water (14Á77 ll). All qPCR reactions were performed in triplicate. After qPCR reactions, the Ct values were acquired by using a fixed threshold value. The expression levels of EBV miRNAs were normalized to the levels of U6 snRNA, which was demonstrated to be expressed stably in the serum according to previous studies. The 2 -DDCt equation [DDCt 5 (Ct miRNACt U6 ) target -(Ct miRNA -Ct U6 ) control ] was used as a calculation method to test the amount of miRNA relative to the internal control U6 snRNA. In controls, the Ct value of U6 snRNA was 27Á90 6 0Á10; in MS patients, the Ct value of U6 snRNA was 27Á86 6 0Á20 (P 5 0Á86). To quantify further and evaluate serum EBV miRNAs as disease markers, absolute miRNAs concentrations were determined using a calibration curve method. Calibration curves for each assay were prepared using 10-fold serial dilutions of synthetic single-strand miRNAs for the target miRNAs (synthesized by GenePharma, Shanghai, China). Using the calibration curves, the concentrations of miRNAs were calculated and then normalized to the sample volume. 
Target prediction of miRNAs
TargetScan Human Custom (release 5.2) [27] and RNAhybrid software [28] were used to predict the target mRNAs containing the binding site of the seed region (positions 2-7 of miRNA) of up-regulated circulating EBV miRNAs.
Luciferase reporter assays
Luciferase reporter experiments were conducted to confirm the direct targets of up-regulated circulating EBV miRNAs. The fragment containing the full-length 3' untranslated region (UTR) of the target genes was cloned into the pEZX-MT05 plasmid. HEK 293 cells were seeded at a density of 1 3 10 6 per well in six-well culture plates, cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum. Luciferase assays were performed in triplicate using the Luc-Pair TM miR luciferase assay kit, according to the manufacturer's protocol.
Statistical analysis
The results of miRNAs levels are expressed as the mean 6 standard error of the mean (s.e.m.). Statistical differences are considered significant at P < 0Á05. We used Student's ttest to compare the concentrations of serum EBV miRNAs between MS patients and healthy controls. Spearman's rank correlation coefficient was used to examine the correlation between miRNAs expression levels and the expanded disability status scale (EDSS) scores. Receiver operating characteristic (ROC) analysis was used to evaluate the identified miRNAs as diagnostic biomarkers. Area under the ROC curve (AUC) was estimated and reported with its correspondent 95% confidence interval (CI). Statistical analysis was performed using SPSS version 22.0 software.
Results
Ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 are up-regulated in the sera of MS patients
To explore the expression of EBV miRNAs in patients with MS, we conducted a comprehensive profiling of 44 mature EBV miRNAs using commercially available hydrolysis stem-loop TaqMan probes (Supporting information, Table  S1 ). The expression levels were examined by qRT-PCR using a set of serum samples from 30 RRMS patients at relapse and 30 matched healthy controls. Twenty-four EBV miRNAs were undetectable or barely detectable in more than 90% of the samples (average Ct value > 35 or the approximate background Ct value). Twenty EBV miRNAs were expressed robustly and detectable in all tested samples. Ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 showed significantly increased expression in MS patients compared with healthy controls (fold changes 5 1Á48 and 1Á33, P 5 0Á0005 and 0Á0004, respectively) (Fig. 1a,b) , while the remaining 18 miRNAs showed no significant difference (Supporting information, Table S2 ).
Expression of ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 in MS patients is correlated positively with EDSS score and allows for discrimination of MS patients from healthy controls
We further analysed the association between the expression levels of ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 with the EDSS scores of MS patients using Spearman's rank correlation coefficient. Here we showed that the elevated expression of ebv-miR-BHRF1-2-5p (r s 5 0Á62, P 5 0Á0002) and ebv-miR-BHRF1-3 (r s 5 0Á43, P 5 0Á017) were associated The concentrations of ebv-miR-BHRF1-3 in controls and MS patients were 2946Á14 6 129Á68 and 3929Á94 6 229Á82 fmol/l, respectively (P 5 0Á0004, fold change 5 1Á33). [Colour figure can be viewed at wileyonlinelibrary.com] positively with EDSS scores of MS patients (Fig. 2a,b) . ROC analyses further revealed the value of ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 as biomarkers for MS. ROC curves were drawn using the absolute expression levels of individual miRNAs and their combinations. When independently using ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3, the analyses showed that the AUCs were 0Á74 (95% CI 5 0Á61-0Á86) (Fig. 2c) and 0Á72 (95% CI 5 0Á60-0Á85) (Fig. 2d) , respectively. Using a combination of the two miRNAs, the AUC was 0Á76 (95% CI 5 0Á64-0Á88) (Fig. 2e) .
Prediction and validation of mucosa-associated lymphoid tissue lymphoma transport protein 1 (MALT1) as a direct target of ebv-miR-BHRF1-2-5p
Two computational algorithms (TargetScan Human Custom [27] , RNAhybrid [28] ) and literature reviews were used in combination to identify the target genes of ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3. Among the hundreds of candidate genes, MALT1 was predicted to have two potential binding sites for ebv-miR-BHRF1-2-5p on the 3' untranslated region (3' UTR). The predicted conjugation between the seed region of ebv-miR-BHRF1-2-5p and the binding sites (on positions 3519 and 4319) within the MALT1 mRNA is illustrated in Fig. 3a . Furthermore, literature reviews showed that MALT1 played considerable roles in immune homeostasis [29, 30] . Therefore, we presumed that MALT1 was a potential target of ebv-miR-BHRF1-2-5p. Subsequently, we co-transfected HEK293 cells with luciferase report vectors containing MALT1 3' UTR binding sites and ebv-miR-BHRF1-2-5p or scrambled control RNA. Luciferase reporter assays confirmed that ebv-miR-BHRF1-2-5p suppressed the luciferase activity significantly in contrast to the control RNA (Fig. 3b) . Additionally, we discovered a binding site for ebv-miR-BHRF1-3 within the mRNA of PTEN (phosphatase and tensin homologue deleted on chromosome 10), which has been confirmed previously as a target of ebv-miR-BHRF1-3 [31] .
Discussion
Previous studies have revealed that miRNAs encoded by EBV are associated with the aetiopathogenesis of neoplastic diseases, including nasopharyngeal carcinoma [19] , leukaemia and Burkitt's lymphoma [20] , and potentially exert the anti-apoptotic function by suppressing the expression of PUMA (p53 up-regulated modulator of apoptosis) and pro-apoptotic protein Bid (the BH3-interacting domain death agonist) [32, 33] . Moreover, accumulating studies have highlighted the roles of EBV miRNAs in the regulation of the host's immune response. For example, ebv-miR-BHRF1-3 could inhibit CXCL-11 (C-X-C motif chemokine ligand 11), an interferon (IFN)-inducible T cell attracting chemokine [34] . Ebv-miR-BART15 potentially target NLRP3 (nucleotide-binding oligomerization domain-like receptor protein 3) and reduce endogenous NLRP3 protein levels and IL-1b production [35] . MICB (MHC class Irelated genes B) and IPO7 (Importin 7), which are involved in immune recognition of infected cells and the innate immunity, are the targets of ebv-miR-BART2-5p and ebvmiR-BART3, respectively [26, 36] . These findings showed that EBV miRNAs may lead to immune imbalance and autoimmune diseases. However, the expression of EBV miRNAs in MS patients and the connection with the pathogenesis of MS have not been studied systemically.
In this study, we investigated the expression profile of 44 EBV miRNAs in the sera of 30 RRMS patients at relapse and 30 matched controls using TaqMan probe-based qRT-PCR assays. The expression levels of two BHRF1 miRNAs, including ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3, were elevated noticeably and correlated positively with EDSS scores of MS patients. In ROC analyses, the AUC was 0Á76 when using a combination of the two miRNAs, confirming that ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 allow discrimination of MS patients from healthy control subjects. Previous studies have shown that ebv-miR-BHRF1-2 and ebv-miR-BHRF1-3 were increased rapidly followed by the entry of EBV into the lytic cycle [37] , which was related to the disease activity in MS patients [38] . The specific elevated expressions of ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 are related to the activation of EBV, which may contribute to the relapse of MS and suggest a potential role in the pathogenesis of MS. Recent studies have discovered that mature EBV miRNAs are transported by exosomes, which protect them from degradation by RNases [39] . This implies that EBV-encoded miRNAs are stable in the serum so that they can be used as a diagnostic marker and monitor of EBV-associated disorders, including MS [40] . EBV miRNAs may also be transferred into noninfected recipient cells via exosomes, suggesting a role of intercellular communication in EBV biology [41] .
Furthermore, we preliminarily validated that MALT1 may be a target of ebv-miR-BHRF1-2-5p. The latest researches demonstrated that MALT1 is indispensable for the development of regulatory T cells (T regs ) and plays a considerable role in immune homeostasis [29, 30] . Mice with inactivation of the MALT1 protease activity showed absence of T regs , increased T helper type 1 (Th1) and Th2 cells and elevated production of IFN-g and interleukin (IL)-4, which induced imbalance of immunity, causing lymphocyte infiltration and multi-organ inflammation [29, 30, 42] . Two recent studies reported that MALT1 deficiency was associated with multi-organ autoimmunity [43, 44] . In addition, the MALT1 expression level was down-regulated in peripheral blood mononuclear cells of patients with rheumatoid arthritis, which was also a systemic autoimmune disease that sometimes overlaps MS [45] . Therefore, we postulated that the up-regulation of ebv-miR-BHRF1-2-5p possibly affects the immune system through inhibiting MALT1. Additionally, ebv-miR-BHRF1-3 was confirmed to target PTEN, a regulator of the phosphatidylinositol 3-kinase (PIK3)/Akt (protein kinase B) survival pathway [31, 46] . PTEN plays multiple regulatory roles in the pathogenesis of autoimmunity [47] , including maintaining the expression of the transcription factor forkhead box protein 3 (FoxP3) and restraining T helper 1 and T follicular helper cell responses [47, 48] . Deficiency of PTEN leads to systemic autoimmune disease because of decreased T regs and increased IFN-g [49] . Collectively, the up-regulation of ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 may induce immune imbalance by targeting host genes, suggesting a potential role of EBV miRNAs in the aetiopathogenesis of MS.
In summary, we have demonstrated that ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 are elevated significantly in the sera of RRMS patients at relapse and ebvmiR-BHRF1-2-5p may directly target MALT1, which is a key regulator of immune homeostasis. Although great advances have been made in understanding the protease activity of MALT1 and autoimmune diseases, further investigations of the potential role of EBV-miRNA targeting MALT1 are still required. The specific aberrantly expressed EBV miRNAs in MS possibly regulate the immune response and contribute to the pathogenesis of MS.
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